ARCH Venture Partners IX Overage, L.P., 10% Owner at Lyell Immunopharma, Inc. (LYEL), bought 488,090 shares at $25.61 ($12.5M) on 2026-03-06, disclosed to the SEC on 2026-03-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.